Currently, anti-Axl and anti-EGFR therapies (mAbs and TKIs) have demonstrated significant clinical benefits for the treatment of patient with NPC; however, acquired resistance to Axl or EGFR in tumor cells is a major obstacle in NPC management [51,52]. The gene discussed is EGFR; the disease is nasopharyngeal carcinoma.